Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
|
Prostatic Neoplasms, Castration-Resistant |
Phase 1 |
Australia South Africa |
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
|
Inflammatory Bowel Disease |
|
France |
Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis
|
Seasonal Allergic Rhinitis |
Phase 3 |
Bulgaria Poland |
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
|
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma |
Phase 2 |
Italy France United StatesCanada Spain Poland Netherlands United Kingdom Belgium View All |
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
|
Gastroenteropancreatic Neuroendocrine Tumors |
Phase 4 |
Netherlands Poland ItalyUnited Kingdom View All |
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake
|
Neoplasms |
Phase 1, Phase 2 |
United Kingdom United States NetherlandsAustria Spain View All |
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
|
Dry Age-related Macular Degeneration |
Phase 2 |
United States France SpainGermany United Kingdom Australia View All |
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
|
Spinal Muscular Atrophy (SMA) |
|
United States Russian Federation JapanPortugal Ireland Greece Taiwan Korea, Republic of Israel View All |
LUTATHERA Injection General Use Result Survey
|
Somatostatin Receptor-positive Neuroendocrine Tumor |
|
Japan |
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
|
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers |
Phase 1 |
Japan |